Association Between Long-Term Progesteron Exposure and Intracranial Meningioma: A Case Report in a 44-Year-Old Woman
A Case Report
DOI:
https://doi.org/10.33005/jdiversemedres.v3i4.335Keywords:
Meningioma, Hormonal contraception, Progesterone, Brain tumorAbstract
Background: Meningioma is a common benign intracranial tumor originating from arachnoid cap cells and accounts for approximately one-third of all primary brain tumors. Its higher incidence in women suggests hormonal involvement, particularly from progesterone and progestogen exposure. Prolonged use of hormonal contraceptives, such as depo medroxyprogesterone acetate (DMPA), has been associated with the development and progression of meningioma. Objective: To describe the clinical presentation, neuroimaging findings, management, and possible association between long-term progesterone exposure and intracranial meningioma in a middle-aged woman.
Methods: We report the case of a 44-year-old woman with a history of long-term DMPA use who presented with progressive neurological symptoms. Clinical evaluation, neuroimaging studies, surgical treatment, and histopathological examination were performed and reviewed.
Results: The patient presented with recurrent severe headache, blurred vision, and a progressively enlarging right-sided scalp mass. She had received DMPA injections for more than 15 years. Contrast-enhanced brain CT demonstrated a well-defined right frontotemporal extra-axial mass consistent with meningioma. The patient subsequently underwent craniotomy and complete tumor excision. Histopathological examination confirmed a WHO Grade I meningioma with mixed meningothelial and angiomatous patterns.
Conclusion: This case highlights a potential association between prolonged DMPA exposure and intracranial meningioma. Early recognition of neurological symptoms, timely neuroimaging evaluation, and appropriate surgical management are essential to optimize outcomes. Discontinuation of hormonal exposure should also be considered in patients with hormone-sensitive meningiomas.
Downloads
References
Alruwaili AA, De Jesus O. Meningioma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, et al. Epidemiology of meningiomas. Neurochirurgie. 2018;64(1):5–14.
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2021;22(9):e281–e292.
Wu JS, Shen Y, Sun SH. Imaging and diagnostic advances for intracranial meningiomas. Front Oncol. 2019;9:1511.
Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States, 2016–2020. Neuro Oncol. 2023;25(Suppl 2):i1–i105.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251.
Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4–23.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system. Acta Neuropathol. 2016;131(6):803–820.
Oya S, Sade B, Lee JH. Sphenoid wing meningiomas: clinical features, surgical outcomes, and management considerations. Neurosurg Focus. 2013;35(6):E9.
Raza SM, Gallia GL, Brem H, et al. Perirolandic and parasagittal meningiomas: surgical outcome and neurological morbidity. Neurosurgery. 2010;67(5):1206–1214.
Peyre M, Kalamarides M. Hormonal and genetic factors in meningioma: a focus on progesterone signaling. Endocr Rev. 2023;44(3):389–407.
Cea-Soriano L, Wallander MA, Rodríguez LAG. Hormonal therapies and risk of intracranial meningioma in women: a population-based case–control study. Eur J Neurol. 2022;29(5):1300–1311.
Claus EB, Park PJ, Carroll R, Chan J, Black PM. Progesterone and estrogen receptor expression in meningiomas: epidemiologic and clinicopathologic correlations. J Neurooncol. 2021;152(1):35–43.
Gil M, Giraud S, Chauvet D, et al. Regression of progestin-associated meningiomas after discontinuation of hormonal treatment: a multicenter retrospective study. Acta Neurochir (Wien). 2021;163(8):2321–2330.
Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1821–1834.
Treglia G, Muoio B, Bertagna F. Role of MRI and advanced imaging in the assessment of meningiomas. Front Oncol. 2022;12:842343.
Karsy M, Guan J, Sivakumar W, Couldwell WT. Differential diagnosis of meningiomas: radiologic and clinical features. J Neuroimaging. 2023;33(2):281–294.
Magill ST, Lee DS, Yen AJ, et al. Surgical outcomes and recurrence in meningioma: a contemporary meta-analysis. J Neurosurg. 2023;138(3):713–723.
Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22–39.
Conti A, Pontoriero A, Midili F, et al. Role of radiotherapy and radiosurgery in meningioma management: a systematic review and meta-analysis. Cancers (Basel). 2022;14(5):1155.
Rogers CL, Won M, Vogelbaum MA, et al. High-dose fractionated radiotherapy and stereotactic radiosurgery outcomes for meningioma: a multicenter NRG Oncology/RTOG study. Int J Radiat Oncol Biol Phys. 2021;111(3):709–718.
Mair MJ, Wöhrer A, Furtner J, et al. Neurological and systemic complications in meningioma patients: a systematic review. Cancers (Basel). 2022;14(3):765.
Bassiouni H, Asgari S, Stolke D. Meningiomas of the skull base: clinical features, surgical outcome, and recurrence. Neurosurgery. 2021;88(4):E291–E301.
Caffo M, Germanò A, Barresi V. Malignant progression of meningiomas: molecular mechanisms and therapeutic perspectives. Front Oncol. 2023;13:1105442.
Domingues PH, de Carvalho L, Pires MM, et al. Meningioma recurrence: prognostic factors and long-term outcomes. Neuro Oncol Adv. 2023;5(1):vdad015.
Oya S, Sade B, Lee JH. Long-term follow-up strategies for meningioma after surgery or radiosurgery. World Neurosurg. 2022;163:e204–e212.
Froelich S, Battisti S, Levy D, et al. Hormone withdrawal and spontaneous regression of meningiomas: evidence from clinical cases and mechanistic insights.
Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M, et al. Use of progestogens and the risk of intracranial meningioma: national case-control study. BMJ. 2024;384:e078078
Liu Y, et al. Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis. eClinicalMedicine. 2026;103791.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Journal of Diverse Medical Research : Medicosphere
This work is licensed under a Creative Commons Attribution 4.0 International License.
CC Attribution 4.0
This journal applies the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.